German and Swedish researchers have presented a strategy to predict and improve chemotherapy outcomes in patients with acute myelogenous leukaemia (AML). Currently, the five-year overall survival rate of AML patients treated with cytarabine (ara-C) standard chemotherapy ranges from 20-70%.
Police investigators today begin searches for perpetrators with conventional DNA profiling – comparing a genetic signature from sperm or hair left at a crime scene with a database of identified offenders. But that doesn’t finger culprits who have never been registered. A growing technology called DNA phenotyping’ is now aimed at interpreting genomic clues about a suspect’s possible external appearance. The science behind it is new, and investigators have to navigate the statistical uncertainties – as well as ethical and legal questions – the technology is raising all over Europe.
https://european-biotechnology.com/wp-content/uploads/2024/04/2017spring-forensic-evidence.jpg6751200Thomas Gabrielczyk/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngThomas Gabrielczyk2017-04-11 16:41:372017-04-11 16:41:37Phenotyping: The hidden mugshot in a culprit’s DNA
Hansa Medical, Lund-based developer of novel immunomodulatory enzymes, has recruited Sam Agus as Chief Medical Officer. Agus joins from H. Lundbeck AS, where he was Chief Specialist, Medical Affairs Neurology.
https://european-biotechnology.com/wp-content/uploads/2024/04/sam-agus.jpg473420h.genrich/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngh.genrich2017-04-11 15:06:102017-04-11 15:06:10Hansa Medical: Taking charge of medical affairs
Spanish Economy Minister Luis de Guindos and EMBL Director-General Iain Mattaj have inked an agreement to host a world-class tissue imaging facility in Barcelona. The EMBL’s 6th site in Europe will start work in September.
Cambridge-based immuno-oncology developer Crescendo Biologics had named Philip Bland-Ward as its Chief Scientific Officer. He joins Crescendo from Kymab where he was responsible for leading its most advanced development programme.
https://european-biotechnology.com/wp-content/uploads/2024/04/philip-bland-ward.jpg472420h.genrich/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngh.genrich2017-04-10 14:07:002017-04-10 14:07:00Crescendo Biologics: Aid for late-stage development
After having received market authorisation in Europe and the US for alectinib as second-line treatment for ALK-positive NSCLC, Roche presents data that qualifies the oral drug as first-line therapy.
/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.png00Thomas Gabrielczyk/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngThomas Gabrielczyk2017-04-10 08:26:112017-04-10 08:26:11Roche’s alectinib superior to crizotinib
French cancer specialist Nanobiotix has closed a €25.1m placement of shares being issued to qualified and institutional investors in the US and Europe. The company will use to funds go push commercialisation of its lead candidate NBTXR3.
As cancer immune therapy specialist Adaptimmune’s R&D pipeline has expanded from 9 to 11 candidates and R&D cost rose from US$40.5m to US$63.8m, the company needed more funds.
In April, Nathalie Moll has taken on her new job as Director General of the European Federation of Pharmaceutical Industries and Associations (EFPIA). Moll is also Secretary General of Europe’s largest biotech industry group EuropaBio.
Blood cancer: Boosting chemotherapy effects
BackgroundGalenica exercises over-allotment option
Latest NewsFollowing its CHF1.901bn IPO at SIX Swiss Exchange on 7 April, Galenica Santé has announced full excercise of the over-allotment option worth CHF248m.
Phenotyping: The hidden mugshot in a culprit’s DNA
BackgroundHansa Medical: Taking charge of medical affairs
AppointmentsSpain establishes world-class disease modeling facility
Latest NewsSpanish Economy Minister Luis de Guindos and EMBL Director-General Iain Mattaj have inked an agreement to host a world-class tissue imaging facility in Barcelona. The EMBL’s 6th site in Europe will start work in September.
Crescendo Biologics: Aid for late-stage development
AppointmentsRoche’s alectinib superior to crizotinib
Latest NewsAfter having received market authorisation in Europe and the US for alectinib as second-line treatment for ALK-positive NSCLC, Roche presents data that qualifies the oral drug as first-line therapy.
Nanobiotix completes €25m private placement
Latest NewsFrench cancer specialist Nanobiotix has closed a €25.1m placement of shares being issued to qualified and institutional investors in the US and Europe. The company will use to funds go push commercialisation of its lead candidate NBTXR3.
Adaptimmune raises US$42m
Latest NewsAs cancer immune therapy specialist Adaptimmune’s R&D pipeline has expanded from 9 to 11 candidates and R&D cost rose from US$40.5m to US$63.8m, the company needed more funds.
EFPIA: Engaging for pharma innovation
AppointmentsIn April, Nathalie Moll has taken on her new job as Director General of the European Federation of Pharmaceutical Industries and Associations (EFPIA). Moll is also Secretary General of Europe’s largest biotech industry group EuropaBio.